Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models

• मुख्य लेखकों: Zhiheng Yu (लेखक), Zihan Lei (लेखक), Xueting Yao (लेखक), Hengbang Wang (लेखक), Miao Zhang (लेखक), Zhe Hou (लेखक), Yafen Li (लेखक), Yangyu Zhao (लेखक), Haiyan Li (लेखक), Dongyang Liu (लेखक), Yifan Zhai (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2022-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Olverembatinib (HQP1351) is a third-generation BCR-ABL tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML) (including T315I-mutant disease), exhibits drug-drug interaction (DDI) potential through cytochrome P450 (CYP) enzymes CYP3A4, CYP2C9, CYP2C19, CYP1A2, and CYP2B6. A p...